EA201691803A1 - HUMAN PLASMA KALLIKREIN INHIBITORS - Google Patents

HUMAN PLASMA KALLIKREIN INHIBITORS

Info

Publication number
EA201691803A1
EA201691803A1 EA201691803A EA201691803A EA201691803A1 EA 201691803 A1 EA201691803 A1 EA 201691803A1 EA 201691803 A EA201691803 A EA 201691803A EA 201691803 A EA201691803 A EA 201691803A EA 201691803 A1 EA201691803 A1 EA 201691803A1
Authority
EA
Eurasian Patent Office
Prior art keywords
plasma kallikrein
human plasma
compounds
kallikrein inhibitors
present
Prior art date
Application number
EA201691803A
Other languages
Russian (ru)
Other versions
EA036251B1 (en
Inventor
Правин Л. КОТИАН
Ярлагадда С. Бабу
Миньвань У
Венкат Р. Чинтаредди
В. Сатиш Кумар
Вэйхэ Чжан
Original Assignee
Байокрист Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байокрист Фармасьютикалз, Инк. filed Critical Байокрист Фармасьютикалз, Инк.
Publication of EA201691803A1 publication Critical patent/EA201691803A1/en
Publication of EA036251B1 publication Critical patent/EA036251B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Предложены соединения формулы (I)описанные в настоящей заявке, и их фармацевтически приемлемые соли. Соединения представляют собой ингибиторы калликреина плазмы. Также предложены фармацевтические композиции, содержащие по меньшей мере одно соединение согласно настоящему изобретению, и способы, включающие применение соединений и композиций согласно настоящему изобретению, для лечения и предотвращения заболеваний и состояний, характеризующихся нежелательной активностью калликреина плазмы.The proposed compounds of formula (I) described in this application, and their pharmaceutically acceptable salts. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions containing at least one compound according to the present invention, and methods including the use of the compounds and compositions according to the present invention for treating and preventing diseases and conditions characterized by undesirable activity of plasma kallikrein.

EA201691803A 2014-03-07 2015-03-09 Human plasma kallikrein inhibitors EA036251B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461949808P 2014-03-07 2014-03-07
US201461981515P 2014-04-18 2014-04-18
PCT/US2015/019535 WO2015134998A1 (en) 2014-03-07 2015-03-09 Human plasma kallikrein inhibitors

Publications (2)

Publication Number Publication Date
EA201691803A1 true EA201691803A1 (en) 2017-02-28
EA036251B1 EA036251B1 (en) 2020-10-20

Family

ID=54055948

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691803A EA036251B1 (en) 2014-03-07 2015-03-09 Human plasma kallikrein inhibitors

Country Status (29)

Country Link
US (10) US10125102B2 (en)
EP (3) EP3828173B1 (en)
JP (4) JP6574435B2 (en)
KR (2) KR102510427B1 (en)
CN (2) CN113307772A (en)
AU (3) AU2015226855C1 (en)
BR (1) BR112016020199A8 (en)
CA (2) CA3164693A1 (en)
CY (1) CY1123810T1 (en)
DK (2) DK3113772T3 (en)
EA (1) EA036251B1 (en)
ES (2) ES2836373T3 (en)
FR (1) FR21C1048I2 (en)
HR (2) HRP20221373T1 (en)
HU (3) HUE052668T2 (en)
IL (2) IL247518B (en)
LT (3) LT3828173T (en)
MA (1) MA53399B1 (en)
MX (2) MX2020013059A (en)
NL (1) NL301142I2 (en)
NO (1) NO2022046I1 (en)
NZ (2) NZ724250A (en)
PH (1) PH12016501750A1 (en)
PL (2) PL3828173T3 (en)
PT (2) PT3113772T (en)
RS (2) RS63763B1 (en)
SG (2) SG11201607267SA (en)
SI (1) SI3113772T1 (en)
WO (1) WO2015134998A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014160668A1 (en) 2013-03-25 2014-10-02 Bristol-Myers Squibb Company Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors
GB2517908A (en) 2013-08-14 2015-03-11 Kalvista Pharmaceuticals Ltd Bicyclic inhibitors
TWI636047B (en) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 Heterocyclic derivatives
US9777001B2 (en) 2014-01-31 2017-10-03 Bristol-Myers Squibb Company Macrocycles with aromatic P2′ groups as factor xia inhibitors
NO2760821T3 (en) 2014-01-31 2018-03-10
JP6574435B2 (en) 2014-03-07 2019-09-11 バイオクリスト ファーマスーティカルズ，インコーポレイテッドＢｉｏｃｒｙｓｔ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Human plasma kallikrein inhibitor
JP6526796B2 (en) 2014-09-04 2019-06-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Diamide macrocycles that are FXIA inhibitors
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
PT4019022T (en) * 2015-10-01 2024-03-11 Biocryst Pharm Inc Human plasma kallikrein inhibitors
LT3464271T (en) 2016-05-31 2020-09-10 Kalvista Pharmaceuticals Limited Pyrazole derivatives as plasma kallikrein inhibitors
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
SI3716952T1 (en) 2017-11-29 2022-04-29 Kalvista Pharmaceuticals Limited Dosage forms comprising a plasma kallikrein inhibitor
GB201721515D0 (en) * 2017-12-21 2018-02-07 Kalvista Pharmaceuticals Ltd Dosage forms comprising a plasma kallikrein inhibtor
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
EP3841086A4 (en) 2018-08-20 2022-07-27 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
AR116951A1 (en) * 2018-11-02 2021-06-30 Biocryst Pharm Inc CRYSTALLINE SALTS FROM A PLASMA CALICREIN INHIBITOR
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2020210368A1 (en) * 2019-04-08 2020-10-15 Biocryst Pharmaceuticals, Inc. Plasma kallikrein inhibitors and methods of use thereof in ocular disorders
WO2021025969A1 (en) 2019-08-02 2021-02-11 Teva Pharmaceuticals International Gmbh Solid state forms of berotralstat
MX2022001608A (en) * 2019-08-06 2022-03-11 Biocryst Pharm Inc Process-scale synthesis of a plasma kallikrein inhibitor.
CN114206852A (en) 2019-08-09 2022-03-18 卡尔维斯塔制药有限公司 Plasma kallikrein inhibitors
EP4017850A1 (en) * 2019-08-21 2022-06-29 Kalvista Pharmaceuticals Limited Enzyme inhibitors
TW202144331A (en) * 2020-02-13 2021-12-01 德商百靈佳殷格翰國際股份有限公司 Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors
US11814371B2 (en) 2020-03-04 2023-11-14 Medshine Discovery Inc. Heterocyclic compound
AU2021292449A1 (en) * 2020-06-16 2023-02-02 Merck Sharp & Dohme Llc Plasma kallikrein inhibitors
WO2022060842A1 (en) * 2020-09-15 2022-03-24 The Trustees Of Columbia University In The City Of New York Systems and methods for predicting graft dysfunction with exosome proteins

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (en) 1983-08-30 1985-04-24 Oreal COSMETIC OR PHARMACEUTICAL COMPOSITION IN AQUEOUS OR ANHYDROUS FORM WHOSE FATTY PHASE CONTAINS OLIGOMER POLYETHER AND NEW OLIGOMER POLYETHERS
LU86084A1 (en) 1985-09-20 1987-04-02 Faco Sa ELECTRIC MASSAGE APPARATUS
US5102417A (en) 1985-11-07 1992-04-07 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
DE3633840A1 (en) 1986-10-04 1988-04-14 Hoechst Ag PHENYLPYRAZOLIC CARBONIC ACID DERIVATIVES, THEIR PRODUCTION AND USE AS PLANT GROWTH REGULATORS AND SAFENERS
US4800882A (en) 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4886062A (en) 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
WO1990013332A1 (en) 1989-05-11 1990-11-15 Cedars-Sinai Medical Center Stent with sustained drug delivery
EP0470246B1 (en) 1990-02-28 1995-06-28 Medtronic, Inc. Intralumenal drug eluting prosthesis
US5419760A (en) 1993-01-08 1995-05-30 Pdt Systems, Inc. Medicament dispensing stent for prevention of restenosis of a blood vessel
US5429634A (en) 1993-09-09 1995-07-04 Pdt Systems Biogenic implant for drug delivery and method
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
NZ336162A (en) * 1996-12-23 2000-09-29 Du Pont Pharm Co pyrrole, tetrazole or pyrazole derivatives useful as factor Xa inhibitors
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
ZA985247B (en) * 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
EA200000048A1 (en) * 1997-06-19 2000-08-28 Дюпон Фармасьютикалз Компани INHIBITORS OF FACTOR XA, CONTAINING A GROUP WITH NEUTRAL P1-SPECIFICITY
US6339099B1 (en) 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
US6271237B1 (en) * 1997-12-22 2001-08-07 Dupont Pharmaceuticals Company Nitrogen containing heteromatics with ortho-substituted P1s as factor Xa inhabitors
BR9813835A (en) * 1997-12-22 2000-10-10 Du Pont Pharm Co Compound, pharmaceutical composition and method of treatment or prevention of a thromboembolic disorder
EP1176140B1 (en) * 1999-02-10 2004-12-29 Mitsubishi Pharma Corporation Amide compounds and medicinal use thereof
WO2000059902A2 (en) * 1999-04-02 2000-10-12 Du Pont Pharmaceuticals Company Aryl sulfonyls as factor xa inhibitors
US20010044445A1 (en) 1999-04-08 2001-11-22 Bamaung Nwe Y. Azole inhibitors of cytokine production
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US6329527B1 (en) 1999-10-21 2001-12-11 Bristol-Myers Squibb Pharma Company Synthesis of 1,3,5-trisubstituted pyrazoles
WO2002000651A2 (en) * 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Factor xa inhibitors
KR100751981B1 (en) 2000-06-27 2007-08-28 라보라토리오스 살바트, 에스.에이. Carbamates derived from arylalkylamines
HUP0500133A2 (en) 2000-09-22 2005-04-28 Bristol-Myers Squibb Pharma Company Efficient process for the preparation of a factor xa inhibitor
PL367064A1 (en) 2001-04-12 2005-02-21 F.Hoffmann-La Roche Ag Dihydro-benzo [b] [1,4] diazepin-2-one derivatives as mglur2 antagonists ii
TWI325302B (en) * 2001-08-13 2010-06-01 Du Pont Benzoxazinone compounds
EP1417200B1 (en) * 2001-08-13 2010-06-02 E.I. Du Pont De Nemours And Company Substituted 1h-dihydropyrazoles, their preparation and use
CN1298706C (en) * 2001-09-21 2007-02-07 杜邦公司 Insecticidal diamides
TW200724033A (en) 2001-09-21 2007-07-01 Du Pont Anthranilamide arthropodicide treatment
US7030141B2 (en) * 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
TW200303309A (en) 2001-12-04 2003-09-01 Bristol Myers Squibb Co Novel n-[4-(1h-imidazol-1-yl)-2-fluorophenyl]-3-trifluoromethyl)-1h-pyrazole-5-carboxamides as factor Xa inhibitors
TW200302225A (en) 2001-12-04 2003-08-01 Bristol Myers Squibb Co Substituted amino methyl factor Xa inhibitors
WO2003099793A1 (en) 2002-05-24 2003-12-04 Takeda Pharmaceutical Company Limited 1,2-azole derivatives with hypoglycemic and hypolipidemic activity
WO2003106427A2 (en) * 2002-06-13 2003-12-24 E.I. Du Pont De Nemours And Company Pyrazolecarboxamide insecticides
DE10229070A1 (en) * 2002-06-28 2004-01-15 Merck Patent Gmbh Phenyl derivatives 5
US6770729B2 (en) 2002-09-30 2004-08-03 Medtronic Minimed, Inc. Polymer compositions containing bioactive agents and methods for their use
CA2512243A1 (en) 2003-01-28 2004-09-16 Aventis Pharma S.A. N-aryl heteroaromatic products, compositions containing same and use thereof
WO2005023761A2 (en) 2003-09-11 2005-03-17 Kemia, Inc. Cytokine inhibitors
WO2005094805A1 (en) * 2004-04-01 2005-10-13 Institute Of Medicinal Molecular Design. Inc. Imine derivative and amide derivative
EP1751112A2 (en) 2004-04-13 2007-02-14 E.I.Du pont de nemours and company Anthranilamide insecticides
WO2005113522A1 (en) 2004-05-07 2005-12-01 Janssen Pharmaceutica, N.V. Azole carboxamide inhibitors of bacterial type iii protein secretion systems
US20060069270A1 (en) 2004-09-27 2006-03-30 Rafael Shapiro Process for the preparation of 1,3,5-trisubstituted pyrazoles via [3+2] cycloaddition
US7381732B2 (en) 2004-10-26 2008-06-03 Bristol-Myers Squibb Company Pyrazolobenzamides and derivatives as factor Xa inhibitors
EP1812421B9 (en) 2004-11-18 2013-09-25 E.I. Du Pont De Nemours And Company Anthranilamide insecticides
US20070060589A1 (en) 2004-12-21 2007-03-15 Purandare Ashok V Inhibitors of protein arginine methyl transferases
GB0516703D0 (en) 2005-08-15 2005-09-21 Syngenta Participations Ag Novel insecticides
JP5186751B2 (en) * 2005-10-14 2013-04-24 住友化学株式会社 Hydrazide compounds and their pest control applications
PT1937664E (en) 2005-10-14 2011-07-07 Sumitomo Chemical Co Hydrazide compound and pesticidal use of the same
DOP2006000234A (en) 2005-10-28 2007-05-31 Lilly Co Eli KINASE INHIBITORS
DK1988777T3 (en) 2006-02-09 2012-01-16 Athersys Inc Pyrazoles for the treatment of obesity and other cns disorders
BRPI0711648A2 (en) * 2006-05-16 2011-11-29 Boehringer Ingelheim Int substituted prolinamides, manufacture and use thereof as medicinal
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
CN101495468A (en) * 2006-07-31 2009-07-29 艾克提弗赛特制药股份有限公司 Inhibitors of plasma kallikrein
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US20120225057A1 (en) 2006-10-11 2012-09-06 Deciphera Pharmaceuticals, Llc Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases
US20100048539A1 (en) * 2006-11-03 2010-02-25 Irm Llc Compounds and compositions as protein kinase inhibitors
US7998995B2 (en) * 2006-12-08 2011-08-16 Exelixis Patent Company Llc LXR and FXR modulators
WO2008104077A1 (en) 2007-02-28 2008-09-04 Methylgene Inc. Small molecule inhibitors of protein arginine methyltransferases (prmts)
WO2008134969A1 (en) 2007-04-30 2008-11-13 Sinochem Corporation Benzamide compounds and applications thereof
CN101298451B (en) 2007-04-30 2013-01-30 中国中化股份有限公司 Benzamide compounds and use thereof
WO2010069502A2 (en) * 2008-12-18 2010-06-24 Bayer Cropscience Ag Tetrazole substituted anthranilic acid amides as pesticides
CN102365278B (en) 2009-03-26 2015-05-06 先正达参股股份有限公司 Insecticidal compounds
US8946204B2 (en) 2009-05-07 2015-02-03 Gruenenthal Gmbh Substituted phenylureas and phenylamides as vanilloid receptor ligands
JP2013515000A (en) 2009-12-18 2013-05-02 アクティベサイト ファーマシューティカルズ インコーポレイティッド Prodrugs for inhibitors of plasma kallikrein
CN102906090B (en) 2010-02-01 2015-06-24 癌症研究技术有限公司 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
WO2011118818A1 (en) 2010-03-26 2011-09-29 味の素株式会社 Amidinoaneline derivative
CN102285963B (en) 2010-06-21 2014-04-09 中国中化股份有限公司 3-methoxy pyrazolecarboxamide compound and application thereof
CA2806634A1 (en) 2010-08-20 2012-02-23 Gruenenthal Gmbh Substituted cyclic carboxamide and urea derivatives as ligands of the vanilloid receptor
AR083817A1 (en) 2010-11-10 2013-03-27 Gruenenthal Gmbh CARBOXAMIDE AND UREA HETEROAROMATIC SUBSTITUTES SUBSTITUTED AS LEGANDS OF THE VANILLOID RECEIVER
EP2702055A1 (en) 2011-04-11 2014-03-05 Nerviano Medical Sciences S.r.l. Pyrazolyl-pyrimidine derivatives as kinase inhibitors
US8691861B2 (en) * 2011-04-13 2014-04-08 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
WO2013036232A2 (en) 2011-09-08 2013-03-14 Deciphera Pharmaceuticals, Llc Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases
CA2854424A1 (en) 2011-11-09 2013-05-16 Grunenthal Gmbh Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an so2-containing group as vanilloid receptor ligands
CN103467380B (en) 2013-09-29 2015-06-24 南开大学 Substituted phenyl pyrazole amide derivative and preparation method and application thereof
JP6574435B2 (en) 2014-03-07 2019-09-11 バイオクリスト ファーマスーティカルズ，インコーポレイテッドＢｉｏｃｒｙｓｔ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Human plasma kallikrein inhibitor
AR116951A1 (en) 2018-11-02 2021-06-30 Biocryst Pharm Inc CRYSTALLINE SALTS FROM A PLASMA CALICREIN INHIBITOR
MX2022001608A (en) 2019-08-06 2022-03-11 Biocryst Pharm Inc Process-scale synthesis of a plasma kallikrein inhibitor.

Also Published As

Publication number Publication date
WO2015134998A1 (en) 2015-09-11
MA53399B1 (en) 2022-10-31
AU2015226855A1 (en) 2016-10-13
NL301142I1 (en) 2021-11-03
US10689346B2 (en) 2020-06-23
SG10202001795XA (en) 2020-04-29
FR21C1048I2 (en) 2022-09-30
EA036251B1 (en) 2020-10-20
KR102510427B1 (en) 2023-03-14
CA2941380C (en) 2022-09-06
HUE060660T2 (en) 2023-04-28
FR21C1048I1 (en) 2021-12-10
CA2941380A1 (en) 2015-09-11
US20190322626A1 (en) 2019-10-24
EP3113772B8 (en) 2020-11-25
NL301142I2 (en) 2021-12-09
PL3113772T3 (en) 2021-04-06
JP2023181543A (en) 2023-12-21
BR112016020199A8 (en) 2021-07-20
US10633345B2 (en) 2020-04-28
EP3113772A4 (en) 2017-08-30
CA3164693A1 (en) 2015-09-11
US10125102B2 (en) 2018-11-13
MA53399A (en) 2021-06-02
US20210078952A1 (en) 2021-03-18
US20180258049A1 (en) 2018-09-13
LT3113772T (en) 2020-12-28
US20210047276A1 (en) 2021-02-18
PH12016501750A1 (en) 2016-11-21
CN106257976A (en) 2016-12-28
AU2015226855C1 (en) 2021-02-11
JP2017507160A (en) 2017-03-16
IL247518A0 (en) 2016-11-30
DK3828173T3 (en) 2022-11-07
AU2020260400B2 (en) 2022-08-11
JP6574435B2 (en) 2019-09-11
SG11201607267SA (en) 2016-09-29
US20230056538A1 (en) 2023-02-23
KR20230042384A (en) 2023-03-28
HRP20201916T1 (en) 2021-01-22
MX2016011468A (en) 2017-01-23
LTC3113772I2 (en) 2023-06-26
US11685721B2 (en) 2023-06-27
US20210047275A1 (en) 2021-02-18
MX2020013059A (en) 2022-10-07
NO2022046I1 (en) 2022-11-07
IL247518B (en) 2021-02-28
PT3828173T (en) 2022-12-05
HUE052668T2 (en) 2021-05-28
US10329260B2 (en) 2019-06-25
US11203574B2 (en) 2021-12-21
LT3828173T (en) 2022-11-10
US11230530B2 (en) 2022-01-25
HUS2100045I1 (en) 2021-11-29
NZ724250A (en) 2022-02-25
NZ762034A (en) 2022-02-25
EP4180424A1 (en) 2023-05-17
US11708332B2 (en) 2023-07-25
AU2020260400A1 (en) 2020-11-26
IL280785A (en) 2021-04-29
JP2019206588A (en) 2019-12-05
SI3113772T1 (en) 2021-01-29
US11708333B2 (en) 2023-07-25
US20230094305A1 (en) 2023-03-30
CN113307772A (en) 2021-08-27
DK3113772T3 (en) 2020-12-07
CN106257976B (en) 2021-02-02
RS63763B1 (en) 2022-12-30
US11192861B2 (en) 2021-12-07
PL3828173T3 (en) 2022-12-19
JP2021169499A (en) 2021-10-28
EP3828173B1 (en) 2022-08-31
LTPA2021524I1 (en) 2021-11-10
BR112016020199A2 (en) 2017-08-15
KR20160130254A (en) 2016-11-10
AU2022259742A1 (en) 2022-12-01
EP3113772B1 (en) 2020-09-09
RS61159B1 (en) 2021-01-29
US20180354906A1 (en) 2018-12-13
ES2836373T3 (en) 2021-06-24
US20230100082A1 (en) 2023-03-30
HRP20221373T1 (en) 2023-01-06
US20170073314A1 (en) 2017-03-16
ES2932406T3 (en) 2023-01-18
PT3113772T (en) 2020-12-15
EP3113772A1 (en) 2017-01-11
JP6915003B2 (en) 2021-08-04
CY1123810T1 (en) 2022-03-24
EP3828173A1 (en) 2021-06-02
AU2015226855B2 (en) 2020-09-03

Similar Documents

Publication Publication Date Title
EA201691803A1 (en) HUMAN PLASMA KALLIKREIN INHIBITORS
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
EA201891191A1 (en) 2-SUBSTITUTED HINAZOLIN COMPOUNDS CONTAINING A SUBSTITUTED HETEROCYCLIC GROUP AND METHODS OF THEIR APPLICATION
EA201790078A1 (en) MNK INHIBITORS AND RELATED METHODS
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
EA201690752A1 (en) INHIBITORS G12C KRAS
EA201692249A1 (en) PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS
EA201891063A1 (en) DERIVATIVES OF DIHYDROIMIDAZOPIRAZINONE APPLICABLE IN THE TREATMENT OF CANCER
EA201692114A1 (en) SUBSTITUTED DIHYDRO-ISOHINOLINE NON COMPOUNDS
EA201692487A1 (en) PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS
EA201692268A1 (en) PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS
EA202090098A1 (en) PHARMACEUTICAL COMPOSITIONS OF THERAPEUTICALLY ACTIVE COMPOUNDS
EA201692266A1 (en) PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS
EA201692265A1 (en) PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS
PH12016501462A1 (en) Neprilysin inhibitors
EA202191548A1 (en) HUMAN PLASMA CALLICREIN INHIBITORS
EA201692481A1 (en) COMBINATION CONTAINING GLUCOCORTICOID AND EDO-S101
EA201692557A1 (en) CINOLYSINUM DERIVATIVES AS PI3K INHIBITORS
EA201692300A1 (en) DERIVATIVES OF CARBOXAMIDE
EA201790830A1 (en) ALDOSTERONSYNTASE INHIBITORS
EA201790253A1 (en) ALDOSTERONSYNTASE INHIBITORS
EA201792264A1 (en) METHODS OF TREATING INFLAMMATORY DISEASES
EA201650003A1 (en) CYCLOALCYL-DIGETERO-CYCLIC DERIVATIVES
EA201891319A1 (en) COMPOUNDS OF ALKYDYDYDROCHINOLINSULPHONAMIDE